protection and immune responses elicited by rsag1-plga nanoparticles in c57bl/6 against toxoplasma gondii

Introduction: this study aimed to evaluate rsag1-plga efficacy as a particulate vaccine in conferring protection against toxoplasma gondii infection in c57bl/6 mice. in light of our previous studies, we studied mice genotype role in eliciting immune responses by rsag1-plga nanoparticles in this study. methods: poly (dl-lactide-co-glycolide) (plga) nanoparticles loaded by rsag1 as a subunit vaccine were prepared, and c57bl/6 mice were subcutaneously immunized twice at a 3-week interval by rsag1-plga, soluble rsag1, blank plga, and one group kept unvaccinated. the characteristics of plga nanoparticles, the amounts of produced ifn-γ, il-10, specific anti-toxoplasmaiggs, and the conferred protection against infection by t. gondii rh tachyzoite were assessed. results: rsag1-plga nanoparticles shared a z-average of about 450nm with negative zeta potential. compared with the negative control group, the mice vaccinated with rsag1-plga nanoparticles produced significantly higher amounts of ifn-γ, specific anti-t. gondii igg antibodies and higher titer of igg2a, which resulted in longer survival times. conclusion: the efficiency of rsag1-plga nanoparticles in inducing humoral and cellular responses and consequently partial protection against acute toxoplasmosis in c57bl/6 was confirmed.